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COPD (chronic obstructive pulmonary 
disease) is a condition caused by 
abnormalities in the inflammatory 
responses of the lungs to irritable particles 
or gases. This is an irreversible condition 
that progresses in later years.(1) 
Pulmonary function tests are the 
parameters for assessing the level of lung 
functioning of a person which is important 
in prognostic, diagnostic, and clinical 
values, clear decrease in lung functioning 
has been reported in patients with diabetes 
from the past decade. Patients with 
diabetes were at risk for developing 
chronic airflow obstruction. (2) 
Diabetes patients have an increased risk of 
developing abnormal lung functioning and 
also in conditions of COPD it even 
worsens the condition, up to 1.6-16% of 
the COPD population were affected due to 
diabetes mellitus. The considerable or 
considered risk factors for the 
development of decreased lung 
functioning were systemic inflammation, 
insulin resistance, and metabolic syndrome 
which was in healthy and nonsmoking 
patients. (3) 
Many studies also suggest that the lung as 
a target organ in diabetes and glycemic 
exposure may be a causation factor for 
reduced lung function. Systemic 
inflammation, hypoxemia, oxidative stress, 
altered gas exchange, and changes in lung 
tissues were the major impacts on the 
respiratory system which were induced by 
hypoglycemia. (4) 
Decreased pulmonary function in patients 
with diabetes mellitus was due to 
biochemical changes in connective tissue 
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constituents of lungs, specifically collagen 
and microangiopathy because of the 
nonenzymatic glycosylation of proteins 
and extracellular matrix of lung 
parenchyma and also elastin. Chronic 
hypoglycemia induced basal lamina 
thickening increased susceptibility to 
infection, and skeletal muscle weakness 
with subsequent sarcolemma.(5) The 
alveolar diffusion capacity was altered due 
to diabetic microangiopathy. Phrenic 
nerves were affected by autonomic 
neuropathy which results in the reduction 
of muscle tone and control of the 
diaphragm. Inflammations cause scarring 
in the walls of the lungs eventually make 
them lose elasticity, which reduces the 
ability to breathe in and breathe out 
limiting the oxygen transferred into the 
bloodstream. In this study, we assessed the 
pulmonary function in COPD patients and 
COPD patients with Diabetes. (6) 
2. Materials and Methods 
The study was conducted in 
Pinnamaneni Siddhartha institute of 
medical sciences and research foundation; 
chinaavutupalli. A detailed proforma was 
filled by the volunteer patients during the 
recruitment, twenty normoglycemic COPD 
patients and twenty COPD with diabetes 
patients were included in the study.  
Inclusion Criteria 
Patient already known COPD and also 
newly diagnosed COPD patients based on 
post-bronchodilator with or without 
Diabetes (7), patient with diabetes already 
on treatment (history of diabetes from past 
4 years). 
Exclusion Criteria 
Patients above 70 years of age. Any 
history of tuberculosis, asthma, cardiac 
diseases, and newly diagnosed diabetes. 
(8) 
Ethics 
Request to conduct the study was 
applied to the ethical committee of 
PSIMS&RF and was kindly accepted to 
perform the study. (9) Participants 
provided informed consent before being 
included in the study and were notified 
that they could quit the study at any time. 
Statistical analysis: 
The data obtained were analyzed by 
unpaired t-test and ANOVA using the 
statistical software SPSS. (10) 
3. Results and Discussion 
The study included 40 volunteered 
patients categorized into 2 groups. 
1. Group A - COPD patients (20) 
2. Group B -COPD with DM (20) 
Most of the patients recruited were 
between the ages of 50-60 years which 
clearly shows that older people were most 
affected by COPD. As for group 1(COPD) 
the values of the test clearly indicate the 
values that represent the general COPD 
patients which were said to be normal for 
their condition and according to the results 
only a few patients can be said to be in 
severe COPD.(11) Whereas group 
2(COPD with DM) the results shows that 
decline in the values of FEV1, FVC, PEF t 
indicate the clear effect of diabetes on lung 
functioning which untreated might cause 
severe organ damage, and also conditions 
of severe and extreme severe COPD was 
found often in this group which shows that 
diabetes shows its impact on the lungs. 
Table 1.Glycemic results in 2 groups 
Tests COPD (Mean±SD) COPD with DM (Mean±SD) P-value 
RBS (mg/dl) - 237.5±2214 0.014 
FBS (mg/dl) - 129.1±11 0.037 
HbA1C 5.4±0.53 8.0±1.93 0.001 
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Table 2.Spirometric results comparison in 2 groups 







FVC pre 1.79±0.30 1.33±0.25 1.15±0.29 0.001 
FVC post 1.89±0.39 1.44±0.30 1.30±0.42 0.001 
FEV1 pre 1.10±0.25 0.73±0.19 0.73±0.27 0.001 
FEV1 post 1.24±0.30 0.86±0.20 0.83±0.39 0.001 
FEV1/FVC pre 0.60±0.07 0.51±0.08 0.67±0.08 0.001 
FEV1/FVC post 0.62±0.09 0.50±0.12 0.64±0.05 0.001 
PEF pre (L/min) 244.06±57.22 175.56±67.77 129±24.55 0.001 
PEF post (L/min) 259.88±70.22 182.8±55.76 150.66±22.66 0.001 
 
We tried to correlate the lung functioning 
in COPD patients with diabetes the results 
of our study show that lung functioning 
decline further greater in diabetes 
association. Irfan et.al studied PFT in 
diabetics and showed that there was a 
significant reduction in FVC, FEV1 and 
also pointed that lung function impairment 
is independent of smoking and likely to be 
a complication of DM itself. Davis et.al 
showed that reduced lung volumes are the 
result of chronic complications of DM and 
are related to glycaemic exposure. (12) 
Detailed pathophysiology of how diabetes 
affects the lungs were still unknown and 
also a matter of interest for a research 
topic. Four causes that were said to cause 
these outcomes were lung elasticity 
reduction which was caused by disrupted 
glycemic control which also causes 
nonenzymatic glycosylation end products. 
Reduction in diffusing capacity and 
pulmonary capillary blood volume due to 
thickened alveolar epithelial basal lamina 
and micro vascular changes in pulmonary 
capillary beds. Phrenic nerves were 
affected by autonomic neuropathy which 
results in reduced muscle tone and control 
over the diaphragm. Hyperglycemia 
increases glucose in airway surface liquid 
serving as a fuel for bacteria and 
subsequent increase in the frequency of 
bacterial pathogens isolated in sputum. 
This study showed that FEV1, FVC, 
FEV1/FVC were decreased in group 2 
(COPD with DM) even more than 
compared to group 1 (COPD). But the 
study was bounded by certain limitations 
due to its sample size and also due to not 
considering a group of only diabetes 
patients and also patients were not retested 
for PFT because some alterations can be 
found due to lifestyle changes. This study 
result shows the decline of lung function in 
DM patients in a long term condition 
including spirometric tests in patients with 
DM is much advisable which helps the 
patients in the long term run of health. 
4. Conclusion 
We conclude that COPD with DM 
patients (group 2) indicates a decline in the 
PFT values than the COPD patients (group 
1). This finding suggests that the lung is 
the target organ in diabetes conditions 
which is independent of smoking so 
patients with DM were suggested to 
undergo PFT with other tests as well. So 
long-term diabetes patients should undergo 
periodic PFT measurements to evaluate 
their lung functioning and their severity of 
damage and thereby could undergo early 
treatment to avoid respiratory collapse 
which reduces morbidity and mortality 
rates of the patients. 
Acknowledgements 
We would like to convey our sincere 
gratitude towards the staff of the 
pulmonary ward in Pinnamaneni 
Siddhartha College of medical sciences 
Atluri et.al                                               Himalayan Journal of Health Sciences                               ISSN: 2582-0737 
© 2021HJHS Journal                                                      2021; 6(3) Page 51 
and research foundation; chinnavutupalli, 
who provide us their facilities and their 
diagnostic equipment to attain the results 
and supported us through the volunteer 
recruiting process.   
Financial Disclosure statement: The 
author received no specific funding for this 
work. 
Conflict of Interest 
The authors declare that there is no 
conflict of interest regarding the 
publication of this article. 
References 
1. Glaser S, Kruger S, Merkel M, Bramlage P, 
Herth FJ. Chronic obstructive pulmonary 
disease and diabetes mellitus: a systematic 
review of the literature. Respiration. 2015 Feb; 
89(3):253-64. 
2. Anuradha Y, Saxena AK, Kusum G, Poonam P, 
Meena G. Study of Pulmonary Function Tests 
in Type 2 Diabetes Mellitus: Case-Control 
Study, IOSR Journal of Dental and Medical 
Sciences. 2013 Oct; 10:74-77.  
3. Rogliani P, Luca G. Lauro D. Chronic 
obstructive pulmonary disease and 
diabetes. COPD Res Pract. 2015 Aug; 1(3):933-
940. 
4. Supriya A, Narmadha MP, Anjali RM, 
Varghese PR, Impact of Diabetes Mellitus on 
Pulmonary Function Tests in COPD Patients, 
Int J Contemp Med Res. 2017 April; 4(4):795-
797. 
5. Raghuveer R, Gopal V. A Comparison of 
Polyherbal Tablets to Treat Type II Diabetes. 
Future J. Pharm. Health Sci. 2021 Mar; 1(2):8-
11. 
6. Kozhevnikova SA, Budnevskiy AV, 
Ovsyannikov ES, Malysh EY, Belov VN. 
Chronic obstructive pulmonary disease and 
diabetes: a look at the epidemiology, 
pathogenetic mechanisms, treatment. 
PatolFiziolEksp Ter. 2016 Oct-Dec; 60(4):122-
7.  
7. Mekov EV, Slavova YG, Genova MP, Tsakova 
AD, Kostadinov DT, Minchev DD, Marinova 
DM, Boyanov MA. Diabetes mellitus type 2 in 
hospitalized COPD patients: impact on quality 
of life and lung function. Folia Medica 2016 
April; 58(1): 36-41. 
8. Zaman SU, Banerjee J, Singhamahapatra A, 
Dey PK, Roy A, Roy K, Roy Basu K. 
Assessment of lung function by spirometry and 
diffusion study and effect of glycemic control 
on pulmonary function in type 2 diabetes 
mellitus patients of the eastern India. J 
ClinDiagn Res. 2014 Nov; 8(11):BC01-4.  
9. Huang H, Guo Q, Li L, Lin S, Lin Y, Gong X, 
Yao J, Liang J, Lin L, Wen J, Chen G. Effect of 
type 2 diabetes mellitus on pulmonary function. 
ExpClinEndocrinol Diabetes. 2014 Jun; 
122(6):322-6. 
10. Ho TW, Huang CT, Ruan SY, Tsai YJ, Lai F, 
Yu CJ. Diabetes mellitus in patients with 
chronic obstructive pulmonary disease-The 
impact on mortality. PLoS One. 2017 Apr 14; 
12(4):e0175794. 
11. Shah SH, Sonawane P, Nahar P, Vaidya S, 
Salvi S. Pulmonary function tests in type 2 
diabetes mellitus and their association with 
glycemic control and duration of the disease. 
Lung India. 2013 Apr; 30(2):108-12. 
12. Davis WA, Knuiman M, Kendall P, Grange V, 
Davis TM. Fremantle Diabetes Study. 
Glycemic exposure is associated with reduced 
pulmonary function in type 2 diabetes: the 
Fremantle Diabetes Study. Diabetes Care. 2004 
Mar; 27(3):752-7. 
 
